TY - JOUR
T1 - Getting out of a wheelchair
T2 - an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
AU - Agbarya, Abed
AU - Melamed-Frank, Meira
AU - Kaidar-Person, Orit
AU - Goldberg-Cohen, Ilana
AU - Nasrallah, Haitam
AU - Wollner, Mira
AU - Bar, Jair
AU - Rennert, Gad
AU - Lejbkowicz, Flavio
N1 - Publisher Copyright:
© 2014, Agbarya et al.; licensee Springer.
PY - 2014/12/30
Y1 - 2014/12/30
N2 - Background: Most patients with non-small cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Advanced NSCLC that contains characteristic mutations in epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). EGFR exon 19 insertions mutations are rare, and response to TKIs is still unclear. Case description: A young Arab patient was diagnosed with metastatic disease of NSCLC harboring an exon 19 insertion of 18 nucleotides. The patient showed a very impressive clinical and radiological response within few weeks treatment with TKI agent. Discussion and evaluation: To our best knowledge, This case is the first case in Arab woman and one of few cases described in the literature with this rare mutation responding to TKIs. Conclusions: Treatment with TKIs should be the standard choice in patients with metastatic disease NSCLC.
AB - Background: Most patients with non-small cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Advanced NSCLC that contains characteristic mutations in epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). EGFR exon 19 insertions mutations are rare, and response to TKIs is still unclear. Case description: A young Arab patient was diagnosed with metastatic disease of NSCLC harboring an exon 19 insertion of 18 nucleotides. The patient showed a very impressive clinical and radiological response within few weeks treatment with TKI agent. Discussion and evaluation: To our best knowledge, This case is the first case in Arab woman and one of few cases described in the literature with this rare mutation responding to TKIs. Conclusions: Treatment with TKIs should be the standard choice in patients with metastatic disease NSCLC.
KW - Epidermal growth factor receptor
KW - Erlotinib
KW - Exon 19 insertion
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84933507191&partnerID=8YFLogxK
U2 - 10.1186/2193-1801-3-507
DO - 10.1186/2193-1801-3-507
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84933507191
SN - 2193-1801
VL - 3
JO - SpringerPlus
JF - SpringerPlus
IS - 1
M1 - 507
ER -